Metoprolol in Patients With HFrEF and COPD (NCT06825728) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Metoprolol in Patients With HFrEF and COPD
311 participantsStarted 2025-02
Plain-language summary
The goal of the clinical trial was to see if Metoprolol was effective in treating patients with heart failure and chronic obstructive pulmonary disease. It will also learn about the safety of Metoprolol. The main questions it aims to answer are:
Did Metoprolol reduce the frequency of all-cause deaths and re-hospitalizations in subjects? What medical problems do participants experience after taking Metoprolol? The researchers will compare different doses of Metoprolol to see the best dose for Metoprolol.
Participants will:
Take Metoprolol 23.75mg/ day or the maximum tolerable dose of Metoprolol daily for 24 months.
Regular outpatient follow-up visits to the research center. Their symptoms and Metoprolol dosage were recorded.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. A definite diagnosis of HFrEF (LVEF≤40%), NYHA II to IV , and the disease is due to ischemic heart disease or dilated cardiomyopathy;
✓. A definite diagnosis of COPD with moderate or higher airflow limitation (FEV1/FVC \< 0.7 and FEV1 \< 80% of the expected value);
✓. Age ≥18 years old;
✓. Informed consent has been obtained and signed.
Exclusion criteria
✕. the dose of Metoprolol before enrollment was more than 23.75mg/d;
✕. Resting heart rate \< 50 beats/min;
✕. Second or third degree atrioventricular block;
✕. Atrial fibrillation;
✕. Sick sinus syndrome;
✕. Systolic blood pressure \< 90mmHg;
✕. Acute attack of bronchial asthma;
What they're measuring
1
Composite endpoints (all-cause death and rehospitalization)
Timeframe: From enrollment to the end of treatment at 24 months.
Trial details
NCT IDNCT06825728
SponsorXiangya Hospital of Central South University